Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com
Investor contact: |
International Media Contact: |
U.S. Media Contact: |
||
S.A. Noonan Communications |
JW Communications |
Rx Communications Group, LLC |
||
Susan A. Noonan |
Julia Wilson |
Paula Schwartz |
||
+1-212-966-3650 |
+44 (0)7818 430877 |
+ 1-917-322-2216 |
||
View original content:http://www.prnewswire.com/news-releases/autolus-therapeutics-submits-fiscal-year-2018-form-20-f-300754699.html
SOURCE